Aberdeen International
TSE:AABAberdeen International Inc., a resource investment and merchant banking company, focuses on small capitalization companies in the rare metals and renewal energy sectors. The company intends to acquire equity participation in pre-IPO and early-stage public resource companies with undeveloped or undervalued resources and assets; companies in need of managerial, technical, and financial resources; companies undervalued in foreign capital markets; and companies operating in jurisdictions with low to moderate local political risk. The company was formerly known as International Catalyst Ventures Inc. and changed its name to Aberdeen International Inc. in November 2001. Aberdeen International Inc. was incorporated in 1987 and is headquartered in Toronto, Canada.
Colonial Properties Trust
NYSE:CLPColonial Properties Trust (the Trust) is a multifamily-focused self-administered equity real estate investment trust (REIT) that owns, operates and develops multifamily communities primarily located in the Sunbelt region of the United States. Its activities include full or partial ownership and operation of 153 properties as of December 31, 2011, located in Alabama, Arizona, Florida, Georgia, Louisiana, Nevada, North Carolina, South Carolina, Tennessee, Texas and Virginia, development of new properties, acquisition of existing properties, build-to-suit development and the provision of management, leasing and brokerage services for commercial real estate. In September 2013, the Company announced the disposition of its Colonial Promenade Tannehill retail asset in Birmingham, Alabama. In October 2013, Mid America Apartment Communities Inc and Colonial Properties Trust announced the completion of the merger of the two companies.
Forty Seven
NASDAQ:FTSVForty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.
Valeura Energy
TSE:VLEValeura Energy Inc., together with its subsidiaries, engages in the exploration, development, and production of petroleum and natural gas in Thailand and in Turkey. The company was founded in 2010 and is headquartered in Singapore.